Novo Holdings Acquires The Ritedose Corporation
January 4, 2022
Novo Holdings A/S has agreed to acquire The Ritedose Corporation from AGIC Capital and Humanwell. Ritedose, a Columbia, South Carolina-based sterile pharmaceutical manufacturer specializing in blow-fill-seal (BFS) technology for ophthalmic, respiratory and vaccine products, employs more than 400 people and will remain led by CEO Jody Chastain; the transaction is expected to close in Q1 2022.
- Buyers
- Novo Holdings A/S
- Targets
- The Ritedose Corporation
- Sellers
- AGIC Capital, Humanwell
- Industry
- Pharmaceuticals
- Location
- South Carolina, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Pfizer Completes Acquisition of Biohaven Pharmaceutical Holding Company Ltd.
October 3, 2022
Biotechnology
Pfizer completed its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC ODT (rimegepant). The all-cash transaction is valued at approximately $11.6 billion and makes Biohaven a wholly owned subsidiary of Pfizer.
-
Roche Acquires Poseida Therapeutics
November 28, 2024
Biotechnology
Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.
-
Bristol Myers Squibb Acquires RayzeBio in $4.1B Deal
December 26, 2023
Biotechnology
Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in an all-cash transaction, valuing the equity at approximately $4.1 billion. The deal is expected to close in the first half of 2024, subject to customary conditions, bringing RayzeBio’s actinium-based radiopharmaceutical platform and clinical pipeline into BMS’s oncology franchise.
-
Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights
October 15, 2025
Pharmaceuticals
Viatris Inc. has acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia‑Pacific markets for Spydia (diazepam) nasal spray. The deal includes an upfront payment to Aculys shareholders with additional milestone and royalty payments, and is intended to strengthen Viatris' presence and CNS capabilities in Japan.
-
SP Industries (Harbour Group) Acquires i-Dositecno
October 31, 2019
Manufacturing
SP Industries, a Harbour Group company, acquired Irta Dosificacio I Technologia S.L. (i-Dositecno), a Spain-based provider of sterile liquid filling lines for pharmaceutical, cosmetic and ophthalmic applications. The acquisition (terms undisclosed) expands SP Industries' fill-finish product portfolio and adds i-Dositecno's European and Asian footprint and engineering/service capabilities to better serve global customers.
-
iMD Companies, Inc. Acquires Riize, LLC
August 29, 2024
Healthcare Services
iMD Companies, Inc. (OTC: ICBU) has completed the acquisition of Riize, LLC, an online telemedicine and pharmacy services provider focused on sexual health and weight loss products. iMD said it will provide resources to scale Riize's product portfolio and subscriber base as part of its healthcare-focused holding company strategy.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.